Lukas Bubendorf

List of Publications by Year
in descending order

261 papers	17,888 citations	21215 62 h-index	16791 127 g-index
272 all docs	272 docs citations	272 times ranked	21780 citing authors

#	Article	IF	Citations
1	High Inter- and Intratumoral Variability of Ki67 Labeling Index in Newly Diagnosed Prostate Cancer with High Gleason Scores. Pathobiology, 2022, 89, 74-80.	1.9	4
2	TargetPlex FFPE-Direct DNA Library Preparation Kit for SiRe NGS panel: an international performance evaluation study. Journal of Clinical Pathology, 2022, 75, 416-421.	1.0	6
3	COVIDâ€19 pandemic impact on cytopathology practice in the postâ€lockdown period: An international, multicenter study. Cancer Cytopathology, 2022, 130, 344-351.	1.4	15
4	A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-GuÃ©rin (BCG) VPM1002BC Immunotherapy in Nonâ€“muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14. European Urology Oncology, 2022, , .	2.6	10
5	Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study. Lung Cancer, 2022, 167, 41-48.	0.9	18
6	NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2022, 17, 793-805.	0.5	6
7	Somatic Features of Response and Relapse in Nonâ€“muscle-invasive Bladder Cancer Treated with Bacillus Calmette-GuÃ©rin Immunotherapy. European Urology Oncology, 2022, 5, 677-686.	2.6	6
8	Alterations in homologous recombination repair genes in prostate cancer brain metastases. Nature Communications, 2022, 13, 2400.	5.8	13
9	Abstract 3073: Bladder cancer patient-derived organoids to decipher cellular plasticity and cancer progression. Cancer Research, 2022, 82, 3073-3073.	0.4	0
10	Informative value of histological assessment of tissue acquired during aquablation of the prostate. World Journal of Urology, 2021, 39, 2043-2047.	1.2	7
11	Putative Malignant Pleural Mesothelioma in situ (MPMIS) with Sequential Acquisition of Genomic Alterations on Fluorescence in situ Hybridization (FISH) Examination. Acta Cytologica, 2021, 65, 99-104.	0.7	7
12	Cytologically targeted next-generation sequencing: a synergy for diagnosing urothelial carcinoma. Journal of the American Society of Cytopathology, 2021, 10, 94-102.	0.2	4
13	Molecular pathology of prostate cancer: a practical approach. Pathology, 2021, 53, 36-43.	0.3	17
14	Cytology of SMARCA4-Deficient Thoracic Neoplasms: Comparative Analysis of SMARCA4-Deficient Non-Small Cell Lung Carcinomas and SMARCA4-Deficient Thoracic Sarcomas. Acta Cytologica, 2021, 65, 67-74.	0.7	23
15	Deciphering the genetic landscape of pulmonary lymphomas. Modern Pathology, 2021, 34, 371-379.	2.9	2
16	Genomic evolutionary trajectory of metastatic squamous cell carcinoma of the lung. Translational Lung Cancer Research, 2021, 10, 1792-1803.	1.3	3
17	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. Journal of Thoracic Oncology, 2021, 16, 686-696.	0.5	13
18	Prostate cancer patientâ€derived organoids: detailed outcome from a prospective cohort of 81 clinical specimens. Journal of Pathology, 2021, 254, 543-555.	2.1	35

#	Article	IF	Citations
19	Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project. Journal of Thoracic Oncology, 2021, 16, 990-1002.	0.5	37
20	Resection of isolated brain metastases in non-small cell lung cancer (NSCLC) patients â€“ evaluation of outcome and prognostic factors: A retrospective multicenter study. PLoS ONE, 2021, 16, e0253601.	1.1	13
21	Integration of transbronchial cryobiopsy into multidisciplinary board decision: a single center analysis of one hundred consecutive patients with interstitial lung disease. Respiratory Research, 2021, 22, 228.	1.4	3
22	Can cytology reliably subtype nonâ€small cell lung carcinomas?. Cytopathology, 2021, , .	0.4	3
23	Molecular testing in stage Iâ€“III non-small cell lung cancer: Approaches and challenges. Lung Cancer, 2021, 162, 42-53.	0.9	22
24	Diagnostic accuracy and clinical implications of robotic assisted MRI-US fusion guided target saturation biopsy of the prostate. Scientific Reports, 2021, 11, 20250.	1.6	7
25	Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression. Nature Communications, 2021, 12, 7033.	5.8	27
26	Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization. Archives of Pathology and Laboratory Medicine, 2020, 144, 735-741.	1.2	25
27	The Paris System for reporting urinary cytology in daily practice with emphasis on ancillary testing by multiprobe FISH. Journal of Clinical Pathology, 2020, 73, 90-95.	1.0	15
28	Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in nonâ€small cell lung cancer. Journal of Pathology, 2020, 250, 19-29.	2.1	92
29	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 499-519.	0.5	203
30	Extensive Emperipolesis of Neoplastic Lymphocytes by Mesothelial Cells in Pleural Effusion Cytology in a Case of a Mediastinal T-Cell Lymphoblastic Lymphoma: A Rare but Diagnostically Useful Phenomenon. Acta Cytologica, 2020, 64, 274-278.	0.7	2
31	Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarraysâ€™ and cross-validation with resections, in patients with, stage Iâ€“III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort. Modern Pathology, 2020, 33, 792-801.	2.9	28
32	PLCÎ³1 suppression promotes the adaptation of KRAS-mutant lung adenocarcinomas to hypoxia. Nature Cell Biology, 2020, 22, 1382-1395.	4.6	16
33	Lamellar Inclusions within Hyperplastic Endoplasmic Reticulum in Benign Mesothelial Cells. Acta Cytologica, 2020, 64, 572-576.	0.7	0
34	A noninterventional, multinational study to assess PDâ€L1 expression in cytological and histological lung cancer specimens. Cancer Cytopathology, 2020, 128, 928-938.	1.4	13
35	Memory CD8+ T Cells Balance Pro- and Anti-inflammatory Activity by Reprogramming Cellular Acetate Handling at Sites of Infection. Cell Metabolism, 2020, 32, 457-467.e5.	7.2	37
36	Global impact of the COVIDâ€19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries. Cancer Cytopathology, 2020, 128, 885-894.	1.4	47

#	Article	IF	Citations
37	Deciphering the clonal relationship between glandular and squamous components in adenosquamous carcinoma of the lung using whole exome sequencing. Lung Cancer, 2020, 150, 132-138.	0.9	15
38	Robust assessment of tumor mutational burden in cytological specimens from lung cancer patients. Lung Cancer, 2020, 149, 84-89.	0.9	14
39	Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples. BMC Cancer, 2020, 20, 366.	1.1	3
40	Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer. American Journal of Surgical Pathology, 2020, 44, e15-e29.	2.1	40
41	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1409-1424.	0.5	182
42	Challenges in the Diagnosis of NTRK Fusion-Positive Cancers. Journal of Thoracic Oncology, 2020, 15, e108-e110.	0.5	7
43	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1599-1610.	0.5	234
44	Patterns of stemnessâ€associated markers in the development of castrationâ€resistant prostate cancer. Prostate, 2020, 80, 1108-1117.	1.2	17
45	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Journal of Thoracic Oncology, 2020, 15, 709-740.	0.5	205
46	The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-GuÃ©rin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data. Journal of Urology, 2020, 203, 283-291.	0.2	10
47	CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo. Journal of Clinical Investigation, 2020, 130, 2435-2450.	3.9	27
48	Narrative review of molecular pathways of kinase fusions and diagnostic approaches for their detection in non-small cell lung carcinomas. Translational Lung Cancer Research, 2020, 9, 2645-2655.	1.3	22
49	Genomic testing among patients (pts) with newly diagnosed advanced non-small cell lung cancer (aNSCLC) in the United States: A contemporary clinical practice patterns study.. Journal of Clinical Oncology, 2020, 38, 9592-9592.	0.8	4
50	Ancillary Studies for Serous Fluids. , 2020, , 129-165.		1
51	Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial). Cancers, 2019, 11, 1099.	1.7	18
52	Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer. Cancer Cytopathology, 2019, 127, 578-585.	1.4	16
53	Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study. Cell Death and Disease, 2019, 10, 534.	2.7	78
54	Handling and reporting of pelvic lymphadenectomy specimens in prostate and bladder cancer: a webâ€based survey by the European Network of Uropathology. Histopathology, 2019, 74, 844-852.	1.6	7

#	Article	IF	Citations
55	PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 67-76.	1.4	13
56	Consistency and reproducibility of nextâ€generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens. Cancer Cytopathology, 2019, 127, 285-296.	1.4	39
57	Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08). British Journal of Cancer, 2019, 120, 968-974.	2.9	7
58	Immunocytochemistry for predictive biomarker testing in lung cancer cytology. Cancer Cytopathology, 2019, 127, 325-339.	1.4	78
59	Urinary Calprotectin loses specificity as tumour marker due to sterile leukocyturia associated with bladder cancer. PLoS ONE, 2019, 14, e0213549.	1.1	4
60	A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. Lung Cancer, 2019, 131, 95-103.	0.9	40
61	Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 377-407.	0.5	212
62	Predictive potential and need for standardization of PD-L1 immunohistochemistry. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 475-484.	1.4	32
63	Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Nonâ€“Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. Clinical Cancer Research, 2019, 25, 64-72.	3.2	159
64	Compressed Sensing Radial Sampling MRI of Prostate Perfusion: Utility for Detection of Prostate Cancer. Radiology, 2019, 290, 702-708.	3.6	27
65	Exploring the spatiotemporal genetic heterogeneity in metastatic lung adenocarcinoma using a nuclei flowâ€sorting approach. Journal of Pathology, 2019, 247, 199-213.	2.1	8
66	Tumor mutational burden assessed by a targeted NGS assay to predict clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.. Journal of Clinical Oncology, 2019, 37, e14266-e14266.	0.8	1
67	Identification and use of treatment (tx) options in patients (pts) with advanced non-small cell lung cancer (aNSCLC) after comprehensive genomic profiling (CGP): A real-world study.. Journal of Clinical Oncology, 2019, 37, 9076-9076.	0.8	0
68	Abstract 4699: Enriching tumor purity using a unique flow-sorting approach to elucidate clonal evolution in matched samples of squamous cell carcinoma of the lung. , 2019, , .		0
69	Abstract 2515: Comprehensive analysis of the histologically distinct components of an adenosquamous carcinoma of the lung. , 2019, , .		0
70	Delineation of human prostate cancer evolution identifies chromothripsis as a polyclonal event and FKBP4 as a potential driver of castration resistance. Journal of Pathology, 2018, 245, 74-84.	2.1	18
71	Quantitative proteomic and phosphoproteomic comparison of human colon cancer DLD-1 cells differing in ploidy and chromosome stability. Molecular Biology of the Cell, 2018, 29, 1031-1047.	0.9	41
72	Detection of ROS1â€positive nonâ€small cell lung cancer on cytological specimens using immunocytochemistry. Cancer Cytopathology, 2018, 126, 421-429.	1.4	30

#	Article	IF	Citations
73	Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. Journal of Thoracic Oncology, 2018, 13, 205-217.	0.5	33
74	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. Journal of Thoracic Oncology, 2018, 13, 413-425.	0.5	66
75	Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1Î± levels under hypoxia. Oncogene, 2018, 37, 4181-4196.	2.6	19
76	Alveolar herniation in transbronchial lung biopsy: a newly recognised diagnostic pitfall. Histopathology, 2018, 72, 710-712.	1.6	0
77	Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry â€" Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort. Journal of Thoracic Oncology, 2018, 13, 1851-1863.	0.5	6
78	Tissue microarray analysis delineate potential prognostic role of Annexin A7 in prostate cancer progression. PLoS ONE, 2018, 13, e0205837.	1.1	6
79	Protocols for Tissue Microarrays in Prostate Cancer Studies. Methods in Molecular Biology, 2018, 1786, 103-116.	0.4	1
80	PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. Journal of Thoracic Oncology, 2018, 13, 1302-1311.	0.5	589
81	Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patientâ€derived xenograft (PDX) models. Prostate, 2018, 78, 1262-1282.	1.2	76
82	Donorâ€derived, metastatic urothelial cancer after kidney transplantation associated with a potentially oncogenic BK polyomavirus. Journal of Pathology, 2018, 244, 265-270.	2.1	34
83	Why Cytology for Molecular Testing? Pros and Cons. , 2018, , 1-10.		0
84	Tumor mutational burden assessed by a targeted NGS assay to predict benefit from immune checkpoint inhibitors in non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, e15075-e15075.	0.8	0
85	Abstract 2184: Enrichment and isolation of tumor cells using a unique flow-sorting approach to decrypt intratumoral heterogeneity in matched samples of squamous cell carcinoma of the lung. , 2018, , .		0
86	Glycine decarboxylase and HIF-1Î± expression are negative prognostic factors in primary resected early-stage non-small cell lung cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 323-330.	1.4	22
87	Tâ€cadherin in prostate cancer: relationship with cancer progression, differentiation and drug resistance. Journal of Pathology: Clinical Research, 2017, 3, 44-57.	1.3	5
88	Influence of hematuria and infection on diagnostic accuracy of urinary LASP1: a new biomarker for bladder carcinoma. Biomarkers in Medicine, 2017, 11, 347-357.	0.6	3
89	Lonely Driver ROS1. Journal of Thoracic Oncology, 2017, 12, 776-777.	0.5	10
90	MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 49-55.	1.4	25

#	Article	IF	Citations
91	Scientific Advances in Thoracic Oncology 2016. Journal of Thoracic Oncology, 2017, 12, 1183-1209.	0.5	40
92	PUB041 HGF, VEGFA and ANGPT2 Predict Clinical Benefit from Bevacizumab and Chemotherapy in Patients with Advanced NSCLC (SAKK19/09). Journal of Thoracic Oncology, 2017, 12, S1471.	0.5	0
93	Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project. Lung Cancer, 2017, 111, 143-149.	0.9	57
94	Comprehensive Molecular Characterization of Urothelial Bladder Carcinoma: A Step Closer to Clinical Translation?. European Urology, 2017, 72, 960-961.	0.9	32
95	Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens. European Respiratory Review, 2017, 26, 170007.	3.0	74
96	The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 468-475.	3.3	52
97	Prognostic value of MIB-1 proliferation index in solitary fibrous tumors of the pleura implemented in a new score â€“ a multicenter study. Respiratory Research, 2017, 18, 210.	1.4	36
98	Consistency and reproducibility of nextâ€generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. Cancer Cytopathology, 2017, 125, 615-626.	1.4	58
99	Abstract 655: Development of IHC staining protocols for assessment of PD-L1 expression in cytological samples. Cancer Research, 2017, 77, 655-655.	0.4	4
100	Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC).. Journal of Clinical Oncology, 2017, 35, 8509-8509.	0.8	25
101	MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling. Oncotarget, 2017, 8, 7964-7976.	0.8	16
102	Urothelial Carcinoma, Cytological Findings. Encyclopedia of Pathology, 2017, , 514-518.	0.0	0
103	Prevalence and clinical correlation of programmed cell death 1 ligand (PD-L1) expression in patients with resected non-small cell lung cancer (NSCLC): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort.. Journal of Clinical Oncology, 2017, 35, 8516-8516.	0.8	0
104	Culture and Drug Profiling of Patient Derived Malignant Pleural Effusions for Personalized Cancer Medicine. PLoS ONE, 2016, 11, e0160807.	1.1	15
105	Intraductal carcinoma of prostate reporting practice: a survey of expert European uropathologists. Journal of Clinical Pathology, 2016, 69, 852-857.	1.0	29
106	Plasma Osteopontin Is a Biomarker Specifically Associated with Bronchiolitis Obliterans Syndrome after HCT. Biology of Blood and Marrow Transplantation, 2016, 22, S417-S418.	2.0	3
107	Common Fluorescence In Situ Hybridization Applications in Cytology. Archives of Pathology and Laboratory Medicine, 2016, 140, 1323-1330.	1.2	38
108	Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 489-503.	1.4	190

#	Article	IF	Citations
109	Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. Histopathology, 2016, 69, 441-449.	1.6	82
110	Urothelial Cancer in Renal Transplant Recipients: Incidence, Risk Factors, and Oncological Outcome. Urology, 2016, 88, 104-110.	0.5	23
111	Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells. Cancer Immunology, Immunotherapy, 2016, 65, 1-11.	2.0	34
112	Ancillary Studies in Urinary Cytology. , 2016, , 115-136.		2
113	Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients. Journal of Thoracic Oncology, 2016, 11, 122-127.	0.5	65
114	Moving Towards Minimally Invasive Genomically Based Diagnosis and Monitoring of Bladder Cancer. European Urology, 2016, 70, 83-84.	0.9	3
115	Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group. Thorax, 2016, 71, 177-184.	2.7	147
116	Prognostic value of the autophagy markers LC3 and p62/SQSTM1 in early-stage non-small cell lung cancer. Oncotarget, 2016, 7, 39544-39555.	0.8	93
117	Abstract 3178: Metastatic urothelial cancer 10 years after transplanting a filial kidney: genomically investigating the perpetrator. , 2016, , .		0
118	Abstract 155: The analysis of the genomic evolution of squamous cell carcinoma of the lung. , 2016, , .		0
119	Abstract 158: Clonal evolution and genomic tumor heterogeneity in non-small cell lung cancer deciphered by multiparameter ploidy profiling. , 2016, , .		0
120	LSC Abstract â€“ System biology of adrenomedullin is controlled via its cell type specific expressed receptors in the human lung. , 2016, , .		0
121	LSC Abstract â€“ System biology of adrenomedullin is controlled via its cell type specific expressed receptors in the human lung. , 2016, , .		0
122	Early development of human lymphomas in a prostate cancer xenograft program using triple knockâ€out Immunocompromised mice. Prostate, 2015, 75, 585-592.	1.2	59
123	Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended. Lung Cancer, 2015, 89, 104-109.	0.9	69
124	Glutathione Sâ€transferaseâ€pi protein expression in prostate cancerâ€“not always a useful diagnostic tool. Histopathology, 2015, 67, 577-579.	1.6	4
125	Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Nonâ€“Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. Clinical Lung Cancer, 2015, 16, 358-365.	1.1	14
126	2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Annals of Oncology, 2015, 26, 1573-1588.	0.6	308

#	Article	IF	Citations
127	Three Genes to Predict Response to Chemotherapy for Bladder Cancer: Individualised Cancer Care at the Doorstep. European Urology, 2015, 68, 968-969.	0.9	3
128	EGFR and IGFâ€1R in regulation of prostate cancer cell phenotype and polarity: opposing functions and modulation by Tâ€cadherin. FASEB Journal, 2015, 29, 494-507.	0.2	17
129	Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. Modern Pathology, 2015, 28, 612-630.	2.9	106
130	Abstract 4924: Multiparameter ploidy profiling: a powerful tool to investigate the genomics of diploid tumor populations. , 2015, , .		0
131	Disease specific effects of adrenomedullin in COPD and asthma derived human bronchial epithelial cells. , 2015, , .		1
132	Influence of Different Components of the Tumor Microenvironment on Human Patient-Derived Lymphoma Cell Engraftment in Immmunodeficient Mice. Blood, 2015, 126, 1459-1459.	0.6	0
133	The Relevance of External Quality Assessment for Molecular Testing for ALK Positive Non-Small Cell Lung Cancer: Results from Two Pilot Rounds Show Room for Optimization. PLoS ONE, 2014, 9, e112159.	1.1	28
134	Ceramic foam plates: a new tool for processing fresh radical prostatectomy specimens. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 637-642.	1.4	4
135	Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project. Journal of Clinical Oncology, 2014, 32, 2780-2787.	0.8	163
136	There is more than meet the eyes in head and neck cytopathology. Diagnostic Cytopathology, 2014, 42, 1-4.	0.5	2
137	MED15, encoding a subunit of the mediator complex, is overexpressed at high frequency in castrationâ€resistant prostate cancer. International Journal of Cancer, 2014, 135, 19-26.	2.3	24
138	MED12 overexpression is a frequent event in castration-resistant prostate cancer. Endocrine-Related Cancer, 2014, 21, 663-675.	1.6	33
139	Multicenter Immunohistochemical ALK-Testing of Nonâ€“Small-Cell Lung Cancer Shows High Concordance after Harmonization of Techniques and Interpretation Criteria. Journal of Thoracic Oncology, 2014, 9, 1685-1692.	0.5	66
140	Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Annals of Oncology, 2014, 25, 1681-1690.	0.6	246
141	An Unexpected Cause of Diffuse Alveolar Hemorrhage in a Kidney Transplant Patient. Respiration, 2014, 87, 504-507.	1.2	3
142	Lungscape: Resected Nonâ€“Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters. Journal of Thoracic Oncology, 2014, 9, 1675-1684.	0.5	31
143	2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Annals of Oncology, 2014, 25, 1462-1474.	0.6	410
144	Targeted multiprobe fluorescence in situ hybridization analysis for elucidation of inconclusive pancreatobiliary cytology. Cancer Cytopathology, 2014, 122, 627-634.	1.4	16

#	Article	IF	Citations
145	Maximum tumor diameter adjusted to the risk profile predicts biochemical recurrence after radical prostatectomy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 429-437.	1.4	6
146	Follow-up in non-small-cell lung cancer. Memo - Magazine of European Medical Oncology, 2014, 7, 97-101.	0.3	0
147	Making Cytological Diagnoses on Digital Images Using the iPath Network. Acta Cytologica, 2014, 58, 453-460.	0.7	11
148	Abstract 4681: The use of patient derived malignant effusions asin vitromodels for a personalized healthcare-approach in anticancer therapy. , 2014, , .		0
149	Abstract 3424: Deciphering the genomic heterogeneity and evolution in malignant melanoma by genomic profiling of clonal tumor populations. , 2014, , .		0
150	Abstract 3423: The genomic evolution of prostate cancer under the selective pressure of anti-androgen therapy. , 2014, , .		0
151	HPV L1 detection discriminates cervical precancer from transient HPV infection: a prospective international multicenter study. Modern Pathology, 2013, 26, 967-974.	2.9	24
152	Lung Histology Predicts Outcome of Bronchiolitis Obliterans Syndrome after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 973-980.	2.0	44
153	STAT5A/B Gene Locus Undergoes Amplification during Human Prostate Cancer Progression. American Journal of Pathology, 2013, 182, 2264-2275.	1.9	44
154	Potential Consequences of Low Biopsy Core Number in Selection of Patients With Prostate Cancer for Current Active Surveillance Protocols. Urology, 2013, 81, 837-843.	0.5	5
155	Klf4 transcription factor is expressed in the cytoplasm of prostate cancer cells. European Journal of Cancer, 2013, 49, 955-963.	1.3	43
156	Heterogeneity of ERG expression in core needle biopsies of patients with early prostate cancer. Human Pathology, 2013, 44, 2727-2735.	1.1	15
157	Treatment and detection of ALK-rearranged NSCLC. Lung Cancer, 2013, 81, 145-154.	0.9	30
158	Prediction of outcome in patients with lowâ€grade squamous intraepithelial lesions by fluorescence in situ hybridization analysis of human papillomavirus, TERC, and MYC. Cancer Cytopathology, 2013, 121, 423-431.	1.4	5
159	VeriStratÂ® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528. Lung Cancer, 2013, 79, 59-64.	0.9	30
160	Characterization and Clinical Relevance of ALDHbright Populations in Prostate Cancer. Clinical Cancer Research, 2013, 19, 5361-5371.	3.2	67
161	Estrogen receptor Î² expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naÃ¯ve prostate cancer and are elevated in castration-resistant disease. Endocrine-Related Cancer, 2013, 20, 403-413.	1.6	43
162	Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives. Expert Review of Anticancer Therapy, 2013, 13, 625-636.	1.1	21

#	Article	IF	Citations
163	Detection of ALK-Positive Nonâ€“Small-Cell Lung Cancers on Cytological Specimens: High Accuracy of Immunocytochemistry with the 5A4 Clone. Journal of Thoracic Oncology, 2013, 8, 1004-1011.	0.5	88
164	Clonal Evolution and Therapeutic Resistance in Solid Tumors. Frontiers in Pharmacology, 2013, 4, 2.	1.6	19
165	EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer. PLoS ONE, 2013, 8, e72966.	1.1	11
166	Genomic analysis and selected molecular pathways in rare cancers. Physical Biology, 2012, 9, 065004.	0.8	8
167	Differential Patterns of Large Tumor Antigen-Specific Immune Responsiveness in Patients with BK Polyomavirus-Positive Prostate Cancer or Benign Prostatic Hyperplasia. Journal of Virology, 2012, 86, 8461-8471.	1.5	15
168	Efficacy of Cetuximab in Metastatic Castration-Resistant Prostate Cancer Might Depend on EGFR and PTEN Expression: Results from a Phase II Trial (SAKK 08/07). Clinical Cancer Research, 2012, 18, 6049-6057.	3.2	36
169	Lung Resection in Hematologic Patients With Pulmonary Invasive Fungal Disease. Chest, 2012, 142, 988-995.	0.4	17
170	Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncology, The, 2012, 13, 1234-1241.	5.1	208
171	ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 157-162.	1.4	11
172	EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 245-257.	1.4	198
173	PAGE4 Positivity Is Associated with Attenuated AR Signaling and Predicts Patient Survival in Hormone-Naive Prostate Cancer. American Journal of Pathology, 2012, 181, 1443-1454.	1.9	24
174	The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer, 2012, 76, 1-18.	0.9	206
175	Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05). Lung Cancer, 2012, 78, 239-244.	0.9	33
176	UroVysionÂ® multiprobe FISH in the triage of equivocal urinary cytology cases. Annales De Pathologie, 2012, 32, e52-e56.	0.1	21
177	Lâ€™hybridation in situ en fluorescence (FISH) utilisant le kit multisonde UroVysionÂ® dans les cytologies urinaires atypiques. Annales De Pathologie, 2012, 32, 438-443.	0.1	5
178	Role of Fluorescence in situ Hybridization in Lung Cancer Cytology. Acta Cytologica, 2012, 56, 611-621.	0.7	54
179	Enhanced Expression of ANO1 in Head and Neck Squamous Cell Carcinoma Causes Cell Migration and Correlates with Poor Prognosis. PLoS ONE, 2012, 7, e43265.	1.1	135
180	High NRBP1 expression in prostate cancer is linked with poor clinical outcomes and increased cancer cell growth. Prostate, 2012, 72, 1678-1687.	1.2	20

#	Article	IF	Citations
181	Report on Norrieâ€™s cytology. Acta Ophthalmologica, 2012, 90, e81-2.	0.6	0
182	Abstract 5386: Immunotherapy of bladder cancer using bacillus calmette guèrin (BCG): Generation of cytotoxic T-cells is BCG strain dependent. Cancer Research, 2012, 72, 5386-5386.	0.4	6
183	Role of KCNMA1 in Breast Cancer. PLoS ONE, 2012, 7, e41664.	1.1	83
184	Deep Clonal Profiling of Formalin Fixed Paraffin Embedded Clinical Samples. PLoS ONE, 2012, 7, e50586.	1.1	42
185	Application of personalized medicine to solid tumors: opportunities and challenges. Swiss Medical Weekly, 2012, 142, w13587.	0.8	9
186	Abstract 556: L-Tag-driven systemic immune regulatory profile as a potential signature for polyomavirus BK involvement in prostate cancer. , 2012, , .		0
187	Abstract 4562: Comprehensive analysis of theTMPRSS2-ERGtranslocation during prostate cancer progression. , 2012, , .		1
188	Can molecular markers stratify the diagnostic value of high-grade prostatic intraepithelial neoplasia?. Human Pathology, 2011, 42, 702-709.	1.1	9
189	Deletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer. Human Pathology, 2011, 42, 983-990.	1.1	28
190	Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer. Journal of Translational Medicine, 2011, 9, 162.	1.8	59
191	Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer. Journal of Pathology, 2011, 223, 543-552.	2.1	34
192	Evaluation of chromosomal aberrations in patients with benign conditions and reactive changes in urinary cytology. Cancer Cytopathology, 2011, 119, 404-410.	1.4	30
193	Multiprobe Fluorescence in situ Hybridization (UroVysion) for the Detection of Urothelial Carcinoma â€“ FISHing for the Right Catch. Acta Cytologica, 2011, 55, 113-119.	0.7	56
194	ROS Signaling by NOX4 Drives Fibroblast-to-Myofibroblast Differentiation in the Diseased Prostatic Stroma. Molecular Endocrinology, 2011, 25, 503-515.	3.7	140
195	Contralateral recurrence of a malignant solitary fibrous tumor of the pleura. Interactive Cardiovascular and Thoracic Surgery, 2011, 12, 306-307.	0.5	3
196	Advancing a clinically relevant perspective of the clonal nature of cancer. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12054-12059.	3.3	101
197	MÃnnliches Genitale. , 2011, , 205-228.		0
198	Harntrakt. , 2011, , 229-255.		0

#	Article	IF	Citations
199	SerÃ¶se HÃ¶hlen. , 2011, , 307-346.		0
200	Abstract 3658: The expression of genes encoding common gamma-chain cytokines is associated with tissue infiltration by CD8+ T cells displaying an â€œexhaustedâ€•phenotype in benign prostatic hyperplasia and prostate cancer. , 2011, , .		0
201	Abstract 3815: Stage I non-small cell lung cancer expressing SOX2 show more recurrence in elderly male patients with non-adenocarcinoma histology. , 2011, , .		0
202	Abstract 1082: The amplification and overexpression of the calcium activated chloride channel TMEM16A (aka DOG1) has a prognostic role in patients with head and neck squamous cell carcinoma. , 2011, , .		0
203	Abstract 2124: Comprehensive analysis of hormone receptor status during prostate cancer progression: A novel prognostic role for pAR and ERbeta. , 2011, , .		0
204	Dysplastic cells in cytological cervical samples show a high incidence of chromosomal abnormalities. Diagnostic Cytopathology, 2010, 38, 28-33.	0.5	1
205	Fluorescence In Situ Hybridization in the Definitive Diagnosis of Malignant Mesothelioma in Effusion Cytology. Chest, 2010, 138, 137-144.	0.4	83
206	Variability in Diagnostic Opinion Among Pathologists for Single Small Atypical Foci in Prostate Biopsies. American Journal of Surgical Pathology, 2010, 34, 169-177.	2.1	50
207	Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocrine-Related Cancer, 2010, 17, 481-493.	1.6	109
208	Gene Profiling of Clinical Routine Biopsies and Prediction of Survival in Nonâ€“Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 181-188.	2.5	44
209	ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Modern Pathology, 2010, 23, 1061-1067.	2.9	114
210	Assessment of mean EGFR gene copy number is a highly reproducible method for evaluating FISH in histological and cytological cancer specimens. Lung Cancer, 2010, 68, 192-197.	0.9	13
211	Transcription Factor Stat3 Stimulates Metastatic Behavior of Human Prostate Cancer Cells in Vivo, whereas Stat5b Has a Preferential Role in the Promotion of Prostate Cancer Cell Viability and Tumor Growth. American Journal of Pathology, 2010, 176, 1959-1972.	1.9	71
212	Anaplastic lymphoma kinase 1 detected by immunohistochemistry in nonâ€“small cell lung cancer: a promising feature?. Human Pathology, 2010, 41, 614-615.	1.1	0
213	Fluorescence in situ hybridization in the diagnosis of urothelial carcinoma. Annales De Pathologie, 2010, 30, 117-118.	0.1	3
214	Abstract 250: Vinculin is a putative amplification target gene at 10q22 in advanced prostate cancer. , 2010, , .		0
215	Risk factors for polyoma virus nephropathy. Nephrology Dialysis Transplantation, 2009, 24, 1024-1033.	0.4	81
216	Re: Aberrant ERG Expression Cooperates with Loss of PTEN to Promote Cancer Progression in the Prostate. European Urology, 2009, 56, 882-883.	0.9	4

#	Article	IF	Citations
217	Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with smallâ€volume or lowâ€grade prostate cancer. International Journal of Cancer, 2009, 124, 2116-2123.	2.3	76
218	The prognostic value of cytology and fluorescence in situ hybridization in the followâ€up of nonmuscleâ€invasive bladder cancer after intravesical Bacillus Calmetteâ€Guã©rin therapy. International Journal of Cancer, 2009, 124, 2899-2904.	2.3	98
219	Abstract A206: Clinically relevant perspectives of the clonal nature of cancer. , 2009, , .		0
220	High expression of indoleamine 2,3-dioxygenase gene in prostate cancer. European Journal of Cancer, 2008, 44, 2266-2275.	1.3	76
221	Stat3 Promotes Metastatic Progression of Prostate Cancer. American Journal of Pathology, 2008, 172, 1717-1728.	1.9	222
222	SIGNIFICANCE OF HIGH-GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA AND ATYPICAL FOCI SUSPICIOUS FOR CARCINOMA IN THE SCREENING POPULATION IN THE FIRST AND SECOND ROUND OF SCREENING. Journal of Urology, 2008, 179, 717-717.	0.2	0
223	TRANSCRIPTION FACTOR STAT5 SYNERGIZES WITH ANDROGEN RECEPTOR IN PROSTATE CANCER CELLS. Journal of Urology, 2008, 179, 186-186.	0.2	0
224	TRANSCRIPTION FACTOR STAT3 PROMOTES METASTATIC PROGRESSION OF PROSTATE CANCER. Journal of Urology, 2008, 179, 392-392.	0.2	0
225	Transcription Factor Stat5 Synergizes with Androgen Receptor in Prostate Cancer Cells. Cancer Research, 2008, 68, 236-248.	0.4	96
226	Leupaxin, a Novel Coactivator of the Androgen Receptor, Is Expressed in Prostate Cancer and Plays a Role in Adhesion and Invasion of Prostate Carcinoma Cells. Molecular Endocrinology, 2008, 22, 1606-1621.	3.7	37
227	Autocrine Prolactin Promotes Prostate Cancer Cell Growth via Janus Kinase-2-Signal Transducer and Activator of Transcription-5a/b Signaling Pathway. Endocrinology, 2007, 148, 3089-3101.	1.4	114
228	Bronchoalveolar lavage quality influences the T4/T8 ratio in sarcoidosis. Respiratory Medicine, 2007, 101, 2025-2030.	1.3	6
229	HER2gene status in primary breast cancers and matched distant metastases. Breast Cancer Research, 2007, 9, R31.	2.2	107
230	B7-03: Prediction of major NSCLC tumor classes and clinical outcome by functional genomics of small bronchoscopic tumor biopsies. Journal of Thoracic Oncology, 2007, 2, S355.	0.5	1
231	ANXA7 expression represents hormoneâ€relevant tumor suppression in different cancers. International Journal of Cancer, 2007, 121, 2628-2636.	2.3	47
232	Ultrastructural and molecular analysis in fatal neonatal interstitial pneumonia caused by a novel ABCA3 mutation. Modern Pathology, 2007, 20, 1009-1018.	2.9	39
233	Multitarget Fluorescence In Situ Hybridization Elucidates Equivocal Lung Cytology. Chest, 2006, 129, 1629-1635.	0.4	37
234	Multi-target fluorescencein situ hybridization in bladder washings for prediction of recurrent bladder cancer. International Journal of Cancer, 2006, 119, 1660-1665.	2.3	103

#	Article	IF	Citations
235	An International Telecytologic Quiz on Urinary Cytology Reveals Educational Deficits and Absence of a Commonly Used Classification System. American Journal of Clinical Pathology, 2006, 126, 294-301.	0.4	79
236	Expression patterns of potential therapeutic targets in prostate cancer. International Journal of Cancer, 2005, 113, 619-628.	2.3	145
237	Multitarget FISH Analysis in the Diagnosis of Lung Cancer. American Journal of Clinical Pathology, 2005, 123, 516-523.	0.4	34
238	Activation of Signal Transducer and Activator of Transcription-5 in Prostate Cancer Predicts Early Recurrence. Clinical Cancer Research, 2005, 11, 5863-5868.	3.2	122
239	Multitarget FISH analysis in the diagnosis of lung cancer. American Journal of Clinical Pathology, 2005, 123, 516-23.	0.4	20
240	Prognostic Impact of ANX7-GTPase in Metastatic and HER2-Negative Breast Cancer Patients. Clinical Cancer Research, 2004, 10, 2344-2350.	3.2	42
241	Signal Transducer and Activator of Transcription-5 Activation and Breast Cancer Prognosis. Journal of Clinical Oncology, 2004, 22, 2053-2060.	0.8	217
242	UroVysionâ„¢ Multiprobe FISH in Urinary Cytology. , 2004, 97, 117-132.		16
243	Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate, 2003, 55, 20-29.	1.2	115
244	Expression of NKX3.1 in normal and malignant tissues. Prostate, 2003, 55, 111-117.	1.2	85
245	Basal Activation of Transcription Factor Signal Transducer and Activator of Transcription (Stat5) in Nonpregnant Mouse and Human Breast Epithelium. Molecular Endocrinology, 2002, 16, 1108-1124.	3.7	72
246	DNA image cytometry and fluorescence in situ hybridization for noninvasive detection of urothelial tumors in voided urine. Cancer, 2002, 96, 374-379.	2.0	40
247	Amplification of EIF3S3 Gene Is Associated with Advanced Stage in Prostate Cancer. American Journal of Pathology, 2001, 159, 2089-2094.	1.9	115
248	ANX7 as a Bio-Marker in Prostate and Breast Cancer Progression. Disease Markers, 2001, 17, 115-120.	0.6	32
249	Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughputin situ studies. Journal of Pathology, 2001, 195, 72-79.	2.1	355
250	Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. Journal of Pathology, 2001, 194, 349-357.	2.1	274
251	Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization. Prostate, 2001, 46, 184-190.	1.2	76
252	Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene, 2001, 20, 6718-6723.	2.6	122

#	Article	IF	Citations
253	Multiprobe FISH for Enhanced Detection of Bladder Cancer in Voided Urine Specimens and Bladder Washings. American Journal of Clinical Pathology, 2001, 116, 79-86.	0.4	223
254	Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Human Pathology, 2000, 31, 578-583.	1.1	1,483
255	High-Throughput Tissue Microarray Analysis to Evaluate Genes Uncovered by cDNA Microarray Screening in Renal Cell Carcinoma. American Journal of Pathology, 1999, 154, 981-986.	1.9	376
256	Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Medicine, 1998, 4, 844-847.	15.2	3,661
257	EGF-r gene copy number changes in renal cell carcinoma detected by fluorescencein situ hybridization. , 1998, 184, 424-429.		52
258	Comparative genomic hybridization reveals frequent chromosome 13q and 4q losses in renal carcinomas with sarcomatoid transformation. , 1998, 185, 382-388.		41
259	Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Human Pathology, 1998, 29, 949-954.	1.1	97
260	FOCAL NEUROENDOCRINE DIFFERENTIATION LACKS PROGNOSTIC SIGNIFICANCE IN PROSTATE CORE NEEDLE BIOPSIES. Journal of Urology, 1998, 160, 406-410.	0.2	55
261	Ki67 LABELLING INDEX: AN INDEPENDENT PREDICTOR OF PROGRESSION IN PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY. , 1996, 178, 437-441.		174